市场调查报告书
商品编码
1468259
2024-2032 年肾上腺素自动注射器市场报告(按剂量、应用、最终用户和地区)Epinephrine Autoinjector Market Report by Dosage, Application, End User, and Region 2024-2032 |
2023年,全球IMARC Group自动注射器市场规模达24亿美元。过敏人群数量不断增加、自我给药需求不断增加以及智慧肾上腺素自动注射器的推出是推动市场发展的一些关键因素。
肾上腺素自动注射器是一种医疗设备,用于轻鬆注射单剂量肾上腺素,用于治疗蜇伤、虫咬或药物引起的严重过敏反应。它的设计目的是将药物输送到个体的大腿肌肉中,并透过收缩血管和扩张气道来发挥作用,以尽量减少过敏反应的症状。它体积小,易于携带,可由个人或医疗保健专业人员管理。目前,领先的製造商正在推出多剂量、剂量可调的肾上腺素自动注射器,使用户能够根据过敏反应的严重程度调整剂量,提高治疗效果。它们还结合了音讯和视觉说明,使个人在紧急情况下更容易使用它们。
患有过敏和过敏反应的人数不断增加,以及对自我给药药物的需求不断增长,是推动全球肾上腺素自动注射器需求的主要因素之一。此外,关节炎、气喘、癌症和慢性阻塞性肺病(COPD)的盛行率飙升以及人口老化的加剧(更容易出现过敏反应)正在对市场产生积极影响。此外,大众食物过敏发生率的增加也促进了市场的成长。除此之外,许多国家的管理机构正在采取倡议,促进在学校和其他公共场所使用肾上腺素自动注射器。再加上人们对肾上腺素自动注射器的认识不断提高,正在促进市场的成长。此外,主要参与者正在推出智慧肾上腺素自动注射器,这些注射器整合了蓝牙连接、感测器和机器学习等先进技术,使其更加方便、用户友好和有效。领先的参与者还推出了可以连接到智慧型手机或其他设备的行动应用程序,允许远端监控、追踪使用情况和有效期,并确保患者不超过建议的剂量。这些进步还可以帮助预测过敏反应的可能性并提供个人化的治疗建议。再加上将自动体外心臟去颤器 (AED) 纳入肾上腺素自动注射器以提供全面的紧急应变系统,正在为市场创造积极的前景。
The global epinephrine autoinjector market size reached US$ 2.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.0 Billion by 2032, exhibiting a growth rate (CAGR) of 8.21% during 2024-2032. The increasing number of individuals with allergies, rising need for self-administrating medicines, and the launch of smart epinephrine autoinjector represent some of the key factors driving the market.
Epinephrine autoinjector is a medical device used to administer single dose epinephrine easily for treating severe allergic reactions caused by stings, bug bites, or drugs. It is designed to deliver the medication into the thigh muscle of an individual and works by constricting blood vessels and dilating the airways to minimize the symptoms of an allergic reaction. It is small and easy to carry and can be administered by individuals or healthcare professionals. At present, leading manufacturers are introducing epinephrine autoinjector with multiple doses of medications and adjustable dosages that enable the user to adjust the dose according to the severity of the allergic reaction and improve the effectiveness of the treatment. They are also incorporating audio and visual instructions to make it easier for individuals to use them in an emergency.
The increasing number of individuals with allergies and allergic reactions and the rising need for self-administrating medicines represent one of the major factors driving the demand for epinephrine autoinjectors around the world. Moreover, the surging prevalence of arthritis, asthma, cancer, and chronic obstructive pulmonary disease (COPD) and the growing aging population, which is more prone to develop allergic reactions, is influencing the market positively. In addition, the increasing incidence of food allergies among the masses is bolstering the growth of the market. Apart from this, governing agencies of numerous countries are undertaking initiatives to promote the use of epinephrine autoinjectors in schools and other public spaces. This, coupled with the rising awareness about epinephrine autoinjectors, is contributing to the market growth. Furthermore, key players are introducing smart epinephrine autoinjectors that are integrated with advanced technologies, including Bluetooth connectivity, sensors, and machine learning, to make them more convenient, user friendly, and effective. Leading players are also launching mobile applications that can be connected to smartphones or other devices, allowing remote monitoring, tracking of usage and expiration dates, and ensuring the patient does not exceed the recommended dosage. These advancements can also help predict the likelihood of an allergic reaction and provide personalized recommendations for treatment. This, along with the incorporation of an automated external defibrillator (AED) in epinephrine autoinjectors to offer a comprehensive emergency response system, is creating a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each segment of the global epinephrine autoinjector market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on dosage, application, and end user.
0.15mg Epinephrine Autoinjector
0.3mg Epinephrine Autoinjector
0.5mg Epinephrine Autoinjector
The report has provided a detailed breakup and analysis of the epinephrine autoinjector market based on the dosage. This includes 0.15mg epinephrine autoinjector, 0.3mg epinephrine autoinjector, and 0.5mg epinephrine autoinjector. According to the report, 0.3mg epinephrine autoinjector represented the largest segment.
Under 6 Years
Over 12 Years
A detailed breakup and analysis of the epinephrine autoinjector market based on the application has also been provided in the report. This includes under 6 years, 6 to 12 years, and over 12 years. According to the report, 6 to 12 years represented the largest segment.
Hospitals
Clinics
Others
The report has provided a detailed breakup and analysis of the epinephrine autoinjector market based on the end user. This includes hospitals, clinics, and others. According to the report, hospitals represented the largest segment.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for epinephrine autoinjectors. Some of the factors driving the North America epinephrine autoinjector market included the rising prevalence of allergies, increasing awareness about anaphylaxis, and the availability of cost-effective generic versions of autoinjectors.
The report has also provided a comprehensive analysis of the competitive landscape in the global epinephrine autoinjector market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Adamis Pharmaceuticals Corporation, Amneal Pharmaceuticals Inc., Antares Pharma Inc, Bausch Health, Kaleo Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.